Status:

COMPLETED

Exploratory Study of the Microbiome of Upper Gastrointestinal in the Pathogenesis of Multiple Primary Lung Cancer

Lead Sponsor:

Beijing Haidian Hospital

Conditions:

Multiple Primary Lung Cancer

Microbial Colonization

Eligibility:

All Genders

18+ years

Brief Summary

This is an exploratory, single-center, being conducted at Beijing Haidian Hospital in order to detect the relationship between microbiome of upper gastrointestinal and pathogenesis of multiple primary...

Detailed Description

This study intends to analyze the bacterial community structure of respiratory tract, upper digestive tract, lesion and adjacent to cancer in patients with multiple primary lung cancer, and to explore...

Eligibility Criteria

Inclusion

  • At least 18 years of age (including 18 years of age, male or female) and voluntarily signed informed consent;
  • Chest CT imaging showed at least 2 pulmonary nodules with a diameter of less than 3cm in ipsilateral lung, and imaging diagnosis of highly suspicious multiple primary lung cancer
  • No surgical contraindication, surgical resection is feasible, and postoperative pathology is diagnosed as multiple primary lung cancer according to Martini and Melamed criteria and gene testing
  • The amount of at least 2 or more tissues removed from multiple pulmonary nodules must meet the requirements of pathological diagnosis, molecular detection and microflora detection

Exclusion

  • under 18 years of age (excluding 18 years of age, male or female) or unwilling to sign informed consent;
  • severe heart, liver, brain, kidney and other important organ diseases and bone marrow hematopoietic dysfunction;
  • Preoperative examination of patients who cannot tolerate surgical resection
  • Patients who received antibiotics within 1 week before surgery E) Resected multiple pulmonary nodules with pathologically proven lung cancer of less than 2 patients
  • Multiple nodules resected were confirmed to be metastases, not primary lung cancer

Key Trial Info

Start Date :

January 6 2023

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 25 2024

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT06973499

Start Date

January 6 2023

End Date

December 25 2024

Last Update

May 15 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Beijing Haidian Hospital

Beijing, China, China, 100080